This company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsAcorda Therapeutics (CDG) 주식 개요A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. 자세히 보기CDG 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성3/6배당0/6강점지난 5년 동안 수입이 매년 10.3% 증가했습니다.위험 분석주식은 유동성이 매우 낮습니다의미 있는 시가총액이 없습니다(€14M)지난 1년 동안 주주가 희석되었습니다.모든 위험 점검 보기CDG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW488,799 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG488,799 investors already sharing narrativesYour Fair Value€Current Price€8.4262.9% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-222m589m2016201920222025202620282031Revenue US$12.1mEarnings US$2.2mAdvancedSet Fair ValueView all narrativesAcorda Therapeutics, Inc. 경쟁사MedigeneSymbol: XTRA:MDG1Market cap: €1.8mco.donSymbol: XTRA:CNWMarket cap: €6.5mPaionSymbol: XTRA:PA8Market cap: €2.6mHeidelberg PharmaSymbol: XTRA:HPHAMarket cap: €115.1m가격 이력 및 성과Acorda Therapeutics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$8.4252주 최고가US$21.8052주 최저가US$5.64베타1.431개월 변동0%3개월 변동-6.83%1년 변동10.25%3년 변동-83.90%5년 변동-99.70%IPO 이후 변동-98.76%최근 뉴스 및 업데이트공고 • Aug 14First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Acorda Therapeutics, Inc. on August 13, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e. up to September 30, 2024, and November 29, 2024, respectively.공고 • Aug 13Acorda Therapeutics Files Form 15Acorda Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share.공고 • Jul 12Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. The acquisition is subjected to the approval by regulatory board, court approval and antitrust regulations. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Scott Talmadge, Adam Golden, Sarah Ghulamhussain, Christopher Stothers, Jenny Leahy, Meghan Rissmiller, Aimen Mir, Stephanie Brown Cripps, Christine Lyon, Joe Soltis, Brock DahlGian Luca Zampa and Sanjay Murti of Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics. As on June 12, 2024 the transaction has been approved by the court. Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. on July 10, 2024.공고 • Jul 04Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.The US Bankruptcy Court approved the solicitation version of the first amended disclosure statement of Acorda Therapeutics, Inc. on July 3, 2024. The debtor had filed its solicitation version of amended disclosure statement in the Court on July 2, 2024. June 28, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is July 31, 2024. The confirmation hearing for the plan has been scheduled for August 7, 2024.공고 • Apr 27Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the ‘Company’) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (‘Nasdaq’) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the ‘Common Stock’) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol ‘ACORQ.’ On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which the company’s common stock will remain registered under Section 12(g) of the Exchange Act.공고 • Apr 17Acorda Therapeutics Announces Delisting from NasdaqAcorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the company’s commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders’ equity of at least $10 million. Trading in the company’s common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company’s common stock is quoted on the OTC Pink Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the ‘ACORQ’ ticker symbol.더 많은 업데이트 보기Recent updates공고 • Aug 14First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Acorda Therapeutics, Inc. on August 13, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e. up to September 30, 2024, and November 29, 2024, respectively.공고 • Aug 13Acorda Therapeutics Files Form 15Acorda Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share.공고 • Jul 12Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. The acquisition is subjected to the approval by regulatory board, court approval and antitrust regulations. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Scott Talmadge, Adam Golden, Sarah Ghulamhussain, Christopher Stothers, Jenny Leahy, Meghan Rissmiller, Aimen Mir, Stephanie Brown Cripps, Christine Lyon, Joe Soltis, Brock DahlGian Luca Zampa and Sanjay Murti of Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics. As on June 12, 2024 the transaction has been approved by the court. Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. on July 10, 2024.공고 • Jul 04Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.The US Bankruptcy Court approved the solicitation version of the first amended disclosure statement of Acorda Therapeutics, Inc. on July 3, 2024. The debtor had filed its solicitation version of amended disclosure statement in the Court on July 2, 2024. June 28, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is July 31, 2024. The confirmation hearing for the plan has been scheduled for August 7, 2024.공고 • Apr 27Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the ‘Company’) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (‘Nasdaq’) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the ‘Common Stock’) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol ‘ACORQ.’ On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which the company’s common stock will remain registered under Section 12(g) of the Exchange Act.공고 • Apr 17Acorda Therapeutics Announces Delisting from NasdaqAcorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the company’s commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders’ equity of at least $10 million. Trading in the company’s common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company’s common stock is quoted on the OTC Pink Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the ‘ACORQ’ ticker symbol.공고 • Apr 12Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite IndexAcorda Therapeutics, Inc removed공고 • Apr 05+ 3 more updatesMotion for Asset Sale Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on April 4, 2024. The debtor seeks the Court’s approval for the sale of substantially all its assets to Merz Pharmaceuticals, LLC, the stalking horse bidder, for a purchase price of $185 million in cash, plus the assumption of certain liabilities pursuant to the asset purchase agreement, dated March 31, 2024. The debtor’s assets include substantially all its assets excluding all Cash, including all restricted cash, and any security and utility deposits, escrow deposits, cash collateral, all insurance policies, all shares of capital stock, partnership interests, membership interests or other equity interests of Sellers or any of their Subsidiaries, and all warrants and options for, and other securities exchange for or convertible or exercisable into, all Leases, the Retained Books and Records, all Seller Benefit Plans, all Contracts that are not Assigned Contracts, any Right to any refund or credit with respect to Taxes relating to any Pre-Closing Tax Period, and all proceeds from chargebacks, Rebates, cash discounts and fees for services payable to Sellers from wholesalers, distributors, hospital customers, and payors. To qualify as a qualified bidder, interested parties should submit their bids by May 16, 2024, along with good-faith deposit in the amount of $18.5 million within three business day of execution of this agreement and $5 million at the time of closing. The initial minimum overbid should be at least $11.75 million more than the initial purchase price. The debtor has scheduled an auction on May 22, 2024. At the auction, the subsequent bids would be in increments of $1 million. The stalking horse bidder would be entitled to a break-up fee of 3.5% of the purchase price and expense reimbursement of 1.5% of the purchase price in case of termination of the asset purchase agreement. The sale hearing is scheduled for May 24, 2024, in case no auction takes place and in case auction takes place will be scheduled for May 31, 2024.공고 • Apr 03Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics.공고 • Apr 02+ 1 more updateMotion for Joint Administration Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on April 1, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Acorda Therapeutics Limited, Biotie Therapies AG, Biotie Therapies, LLC, Civitas Therapeutics, Inc. and Neuronex, Inc., with its own case for administrative and procedural purposes. Acorda Therapeutics, Inc. has been proposed as the lead debtor.공고 • Mar 26Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024Acorda Therapeutics, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Apr 01, 2024공고 • Nov 15Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. provides revenue guidance for the full year 2023. For the full year 2023, the Company reaffirms INBRIJA U.S. net revenue guidance to be $34-$38 million and AMPYRA net revenue guidance to be $65-$70 million.공고 • Nov 07Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJAAcorda Therapeutics, Inc. announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas). INBRIJA is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease (PD) treated with carbidopa/levodopa. Biopas has submitted for marketing approval of INBRIJA in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings for approval of INBRIJA in Chile in late 2023 and in Mexico and Brazil in 2024.공고 • Aug 11Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.공고 • Jun 27Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1). Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.공고 • Jun 06Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select MarketAcorda Therapeutics, Inc. announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time June 5, 2023, and the Company's common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023. The reverse stock split was effected to enable the Company to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. On November 11, 2022, the Company's stockholders authorized the board of directors to effect a reverse stock split by a ratio of any whole number in the range of 1-for-2 to 1-for-20 and a corresponding reduction in the number of authorized shares of common stock. The board of directors subsequently approved the reverse stock split and authorized the filing of the Company's amended and restated certificate of incorporation, as previously announced on May 31, 2023.공고 • Jun 02Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued ListingAcorda Therapeutics, Inc. announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 4:01 p.m. Eastern Time, on June 2, 2023. The company’s common stock will begin trading on a post-split basis at the market open on June 5, 2023. The reverse stock split is being effected to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. The reverse stock split will apply equally to all outstanding shares of the common stock, and each stockholder will hold the same percentage of common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares. The Company will not issue any fractional shares in connection with the reverse stock split, and the number of shares issued will be rounded up to the next whole share. The reverse stock split will not modify the rights or preferences of the common stock. As a result of the proportionate reduction in the number of authorized shares of common stock, the reverse stock split will result in the number of authorized shares of common stock being reduced from 61,666,666 to 3,083,333. As previously reported in the company’s Current Report on Form 8-K filed on November 14, 2022, on November 11, 2022, the company’s stockholders approved a proposal to authorize the company’s board of directors to approve an amendment and restatement of the company’s certificate of incorporation to effect a reverse stock split of the company’s common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of the company’s common stock, within one year following the conclusion of the Special Meeting of Stockholders on November 11, 2022.Reported Earnings • May 15First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)First quarter 2023 results: US$0.69 loss per share (improved from US$1.85 loss in 1Q 2022). Revenue: US$22.3m (down 1.2% from 1Q 2022). Net loss: US$16.8m (loss narrowed 31% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.공고 • May 12Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.Reported Earnings • Mar 11Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)Full year 2022 results: US$3.35 loss per share (improved from US$9.79 loss in FY 2021). Revenue: US$118.6m (down 8.1% from FY 2021). Net loss: US$65.9m (loss narrowed 37% from FY 2021). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.공고 • Feb 16Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that the Nasdaq Hearings Panel has granted the Company's extension request until June 20, 2023 to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. "We are pleased Nasdaq has granted us this extension," said Ron Cohen, M.D., Acorda's President and Chief Executive Officer. "We have announced a detailed business plan and long-term financial guidance to demonstrate what we believe is a path to growing shareholder value in Acorda. The key components of that plan are continued fiscal discipline, growing the Inbrija trajectory, and maintaining the Ampyra brand. We believe that it is in the best interests of our shareholders that we achieve compliance with the bid price rule organically by executing on that plan." If at any time before June 20, 2023 the bid price of Acorda's stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022.공고 • Dec 22Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A HearingAcorda Therapeutics, Inc. announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance with the minimum price of $1.00, the stock is subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to submit such request within the required seven calendar days, which will stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Hearings Panel following the hearing. The Hearings Panel has the discretion to grant the Company an extension through June 17, 2023. At the hearing, the Company intends to present a plan to achieve compliance with the Nasdaq listing requirements and to request additional time to regain such compliance. In the event that the Company receives an extension but cannot regain compliance within the extended time, the Company would effect a reverse stock split under authorization from stockholders received in November 2022. There can be no assurance that the Panel will grant the Company an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Global Select Market. “We believe it is in the best interests of shareholders to allow the stock price to grow organically rather than effecting a reverse stock split, and will discuss this and our long-term plan with the Hearings Panel,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer.Reported Earnings • Nov 18Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 03Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021).공고 • Oct 28Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027Acorda Therapeutics, Inc. Provided earnings guidance for the years of 2022, 2023, 2024, 2025, 2026 and 2027. For the year of 2022, the company expected net revenue to be USD 116.0 million to USD 119.7 million.For the year of 2023, the company expected net revenue to be USD 121.3 million to USD 134.3 million.For the year of 2024, the company expected net revenue to be USD 134.1 million to USD 148.1 million.For the year of 2025, the company expected net revenue to be USD 151.0 million to USD 166.8 million.For the year of 2026, the company expected net revenue to be USD 163.9 million to USD 181.2 million.For the year of 2027, the company expected net revenue to be USD 180.4 million to USD 199.3 million.공고 • Oct 26Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022Acorda Therapeutics, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 01, 2022공고 • Aug 20Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating OfficerAcorda Therapeutics, Inc. announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior Vice President, Operations & Strategic Planning and Susan Way, Senior Vice President, Drug Development and Regulatory Affairs.Reported Earnings • Aug 06Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)Second quarter 2022 results: US$2.78 loss per share (down from US$2.29 loss in 2Q 2021). Revenue: US$31.1m (down 2.3% from 2Q 2021). Net loss: US$46.7m (loss widened 104% from 2Q 2021).공고 • Aug 06Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022Acorda Therapeutics, Inc. provided revenue guidance for the full year 2022. For the full year 2022, Acorda continues to expect AMPYRA net revenue to be $68– $78 million.공고 • Jun 25Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock MarketOn June 22, 2022, Acorda Therapeutics, Inc. (the Company") received a deficiency letter (the Notice") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). The Notice has no immediate effect on the listing of the Company's common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during this 180-day period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The compliance period for the Company will expire on December 19, 2022.공고 • May 17Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022For the full year 2022, Acorda Therapeutics, Inc. continues to expect AMPYRA net revenue to be $68 million– $78 million.Reported Earnings • May 13First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)First quarter 2022 results: US$1.93 loss per share (up from US$3.53 loss in 1Q 2021). Revenue: US$22.5m (down 22% from 1Q 2021). Net loss: US$25.6m (loss narrowed 24% from 1Q 2021).Board Change • May 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Mar 11Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$9.95 loss per share (up from US$12.32 loss in FY 2020). Revenue: US$129.1m (down 16% from FY 2020). Net loss: US$104.0m (loss widened 4.4% from FY 2020). Revenue exceeded analyst estimates by 2.9%.공고 • Mar 07Acorda Therapeutics, Inc. Announces Board ChangesAcorda Therapeutics, Inc. announced on March 3, 2022, John Varian, one of the independent members of the company's Board of Directors, was appointed by the Board to serve on the Board's Audit Committee effective immediately. Mr. Varian was appointed to the Audit Committee to replace John Kelley, the Chair of the Board, who rotated off of the Committee upon Mr. Varian's appointment.Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 11Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: US$31.5m (down 41% from 3Q 2020). Net loss: US$27.1m (down 468% from profit in 3Q 2020).Executive Departure • Aug 26Independent Director Barry Greene has left the companyOn the 20th of August, Barry Greene's tenure as Independent Director ended after 14.6 years in the role. As of June 2021, Barry still personally held only 213.00 shares (€856 worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.Executive Departure • Aug 26Independent Director Catherine D. Strader has left the companyOn the 22nd of August, Catherine D. Strader's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Catherine D.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.Reported Earnings • Aug 09Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$31.8m (down 5.5% from 2Q 2020). Net loss: US$22.9m (loss widened 31% from 2Q 2020).Reported Earnings • May 08First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$28.9m (up 2.7% from 1Q 2020). Net loss: US$33.5m (loss widened 417% from 1Q 2020).공고 • May 07Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021Acorda Therapeutics, Inc. provided financial guidance for the full year of 2021. For the full-year 2021, the company continues to expect AMPYRA net revenue to be $75 million to $85 million.Analyst Estimate Surprise Post Earnings • Mar 05Revenue beats expectationsRevenue exceeded analyst estimates by 2.8%. Over the next year, revenue is expected to shrink by 58% compared to a 62% growth forecast for the Biotechs industry in Germany.Reported Earnings • Mar 05Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$153.0m (down 21% from FY 2019). Net loss: US$99.6m (loss narrowed 64% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 65% per year, which means it is significantly lagging earnings.공고 • Feb 20Acorda Therapeutics Announces Executive ChangesAcorda Therapeutics, Inc. announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning from the Company effective mid-March, 2021. Mr. Lawrence will take a leadership position at an early-stage biotechnology company. Robert Morales, Acorda’s Vice President of Finance and Controller, will assume the roles of interim principal accounting officer and interim principal financial officer.공고 • Feb 13Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million on January 12, 2021. The consideration is subject to certain adjustments and the assumption and is paid in cash. In connection with the transaction, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda. The Asset Purchase Agreement includes customary termination provisions in favor of the Acorda, on the one hand, and Catalent, on the other hand, including if the closing of the transaction has not occurred on or before May 12, 2021. As part of the transaction, Catalent will absorb all Acorda employees who work at the Chelsea facility and certain Acorda employees at the Waltham, Massachusetts facility. Completion of the transaction is subject to customary closing conditions, including, among others, the receipt of certain third party consents and approvals. The transaction is expected to close in the first quarter of 2021. The Acorda intends to use the net proceeds of $70 million received from the transaction for general corporate purposes, which may include funding capital expenditures and the repayment of indebtedness. MTS Health Partners, L.P. is serving as exclusive financial advisor to Acorda Therapeutics on the transaction. Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) on February 11, 2021.공고 • Feb 12Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to CatalentAcorda Therapeutics, Inc. announced that it has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent. Under the terms of the agreement, Catalent has paid Acorda $80 million in cash, resulting in expected net proceeds to Acorda of approximately $74 million after transaction fees and expenses and settlement of customary post-closing adjustments. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda’s patients and continued adherence to best-in-class manufacturing quality and safety standards.공고 • Jan 28Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic IndexAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index공고 • Jan 14Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million on January 12, 2021. The consideration is subject to certain adjustments and the assumption and is paid in cash. In connection with the transaction, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda. The Asset Purchase Agreement includes customary termination provisions in favor of the Acorda, on the one hand, and Catalent, on the other hand, including if the closing of the transaction has not occurred on or before May 12, 2021. As part of the transaction, Catalent will absorb all Acorda employees who work at the Chelsea facility and certain Acorda employees at the Waltham, Massachusetts facility. Completion of the transaction is subject to customary closing conditions, including, among others, the receipt of certain third party consents and approvals. The transaction is expected to close in the first quarter of 2021. The Acorda intends to use the net proceeds of $70 million received from the transaction for general corporate purposes, which may include funding capital expenditures and the repayment of indebtedness. MTS Health Partners, L.P. is serving as exclusive financial advisor to Acorda Therapeutics on the transaction.Is New 90 Day High Low • Jan 14New 90-day high: €5.42The company is up 58% from its price of €3.42 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS US$0.15The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$53.1m (up 11% from 3Q 2019). Net income: US$7.35m (up US$270.9m from 3Q 2019). Profit margin: 14% (up from net loss in 3Q 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 67% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Nov 05Revenue beats expectationsRevenue exceeded analyst estimates by 79%. Over the next year, revenue is expected to shrink by 40% compared to a 305% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Nov 04New 90-day high: €0.89The company is up 55% from its price of €0.57 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.공고 • Oct 28Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020Acorda Therapeutics, Inc. announced that they will report Q3, 2020 results at 4:30 PM, Eastern Standard Time on Nov 03, 2020공고 • Oct 06Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, IncOn September 30, 2020, Steven M. Rauscher notified Acorda Therapeutics, Inc. (the Company) of his decision to resign as a member of the Board of Directors of the Company, effective immediately. At the time of Mr. Rauscher's resignation, he was an independent director and member of the Audit Committee and Chair of the Compliance Committee. Mr. Rauscher indicated that his decision to resign was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.공고 • Sep 21Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI IndexAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index공고 • Jul 02+ 3 more updatesAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value IndexAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value Index주주 수익률CDGDE BiotechsDE 시장7D0%-1.4%-0.4%1Y10.2%11.8%-0.8%전체 주주 수익률 보기수익률 대 산업: CDG은 지난 1년 동안 11.8%의 수익을 기록한 German Biotechs 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: CDG은 지난 1년 동안 -0.8%를 기록한 German 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is CDG's price volatile compared to industry and market?CDG volatilityCDG Average Weekly Movementn/aBiotechs Industry Average Movement7.7%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.8%안정적인 주가: CDG의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine CDG의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트1995111Ron Cohenwww.acorda.com더 보기Acorda Therapeutics, Inc. 기초 지표 요약Acorda Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?CDG 기초 통계시가총액€14.12m순이익 (TTM)-€19.42m매출 (TTM)€108.53m0.1x주가매출비율(P/S)-0.7x주가수익비율(P/E)CDG는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표CDG 손익계산서 (TTM)매출US$116.91m매출원가US$27.38m총이익US$89.53m기타 비용US$110.45m순이익-US$20.92m최근 보고된 실적Jun 30, 2023다음 실적 발표일해당 없음주당순이익(EPS)-16.84총이익률76.58%순이익률-17.89%부채/자본 비율259.6%CDG의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/09/02 09:45종가2023/06/05 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Acorda Therapeutics, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert LeBoyerAegis Capital CorporationChristopher RaymondBairdKenneth TrbovichBrean Capital Historical (Janney Montgomery)17명의 분석가 더 보기
공고 • Aug 14First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Acorda Therapeutics, Inc. on August 13, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e. up to September 30, 2024, and November 29, 2024, respectively.
공고 • Aug 13Acorda Therapeutics Files Form 15Acorda Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share.
공고 • Jul 12Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. The acquisition is subjected to the approval by regulatory board, court approval and antitrust regulations. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Scott Talmadge, Adam Golden, Sarah Ghulamhussain, Christopher Stothers, Jenny Leahy, Meghan Rissmiller, Aimen Mir, Stephanie Brown Cripps, Christine Lyon, Joe Soltis, Brock DahlGian Luca Zampa and Sanjay Murti of Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics. As on June 12, 2024 the transaction has been approved by the court. Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. on July 10, 2024.
공고 • Jul 04Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.The US Bankruptcy Court approved the solicitation version of the first amended disclosure statement of Acorda Therapeutics, Inc. on July 3, 2024. The debtor had filed its solicitation version of amended disclosure statement in the Court on July 2, 2024. June 28, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is July 31, 2024. The confirmation hearing for the plan has been scheduled for August 7, 2024.
공고 • Apr 27Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the ‘Company’) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (‘Nasdaq’) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the ‘Common Stock’) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol ‘ACORQ.’ On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which the company’s common stock will remain registered under Section 12(g) of the Exchange Act.
공고 • Apr 17Acorda Therapeutics Announces Delisting from NasdaqAcorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the company’s commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders’ equity of at least $10 million. Trading in the company’s common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company’s common stock is quoted on the OTC Pink Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the ‘ACORQ’ ticker symbol.
공고 • Aug 14First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Acorda Therapeutics, Inc. on August 13, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e. up to September 30, 2024, and November 29, 2024, respectively.
공고 • Aug 13Acorda Therapeutics Files Form 15Acorda Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share.
공고 • Jul 12Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. The acquisition is subjected to the approval by regulatory board, court approval and antitrust regulations. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Scott Talmadge, Adam Golden, Sarah Ghulamhussain, Christopher Stothers, Jenny Leahy, Meghan Rissmiller, Aimen Mir, Stephanie Brown Cripps, Christine Lyon, Joe Soltis, Brock DahlGian Luca Zampa and Sanjay Murti of Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics. As on June 12, 2024 the transaction has been approved by the court. Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. on July 10, 2024.
공고 • Jul 04Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.The US Bankruptcy Court approved the solicitation version of the first amended disclosure statement of Acorda Therapeutics, Inc. on July 3, 2024. The debtor had filed its solicitation version of amended disclosure statement in the Court on July 2, 2024. June 28, 2024 has been fixed as voting record date. The deadline to vote on the plan and the plan objection deadline is July 31, 2024. The confirmation hearing for the plan has been scheduled for August 7, 2024.
공고 • Apr 27Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024As previously disclosed, on April 3, 2024, Acorda Therapeutics, Inc. (the ‘Company’) was notified by the Listing Qualifications Department of the Nasdaq Stock Market, LLC (‘Nasdaq’) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, $0.001 par value per share (the ‘Common Stock’) from Nasdaq. The Company did not appeal the determination and, therefore, the Company’s Common Stock ceased trading on the Nasdaq on April 12, 2024 and began trading on the Pink Open Market under the symbol ‘ACORQ.’ On April 25, 2024, Nasdaq filed a Form 25 with the U.S. Securities and Exchange Commission to delist the Common Stock from Nasdaq. The delisting of the Common Stock from Nasdaq will become effective on May 5, 2024 and the Common Stock will be deregistered under Section 12(b) of the Exchange Act 90 days after the Form 25 filing, after which the company’s common stock will remain registered under Section 12(g) of the Exchange Act.
공고 • Apr 17Acorda Therapeutics Announces Delisting from NasdaqAcorda Therapeutics, Inc. announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the company’s failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the company’s commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders’ equity of at least $10 million. Trading in the company’s common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company’s common stock is quoted on the OTC Pink Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the ‘ACORQ’ ticker symbol.
공고 • Apr 12Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite IndexAcorda Therapeutics, Inc removed
공고 • Apr 05+ 3 more updatesMotion for Asset Sale Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on April 4, 2024. The debtor seeks the Court’s approval for the sale of substantially all its assets to Merz Pharmaceuticals, LLC, the stalking horse bidder, for a purchase price of $185 million in cash, plus the assumption of certain liabilities pursuant to the asset purchase agreement, dated March 31, 2024. The debtor’s assets include substantially all its assets excluding all Cash, including all restricted cash, and any security and utility deposits, escrow deposits, cash collateral, all insurance policies, all shares of capital stock, partnership interests, membership interests or other equity interests of Sellers or any of their Subsidiaries, and all warrants and options for, and other securities exchange for or convertible or exercisable into, all Leases, the Retained Books and Records, all Seller Benefit Plans, all Contracts that are not Assigned Contracts, any Right to any refund or credit with respect to Taxes relating to any Pre-Closing Tax Period, and all proceeds from chargebacks, Rebates, cash discounts and fees for services payable to Sellers from wholesalers, distributors, hospital customers, and payors. To qualify as a qualified bidder, interested parties should submit their bids by May 16, 2024, along with good-faith deposit in the amount of $18.5 million within three business day of execution of this agreement and $5 million at the time of closing. The initial minimum overbid should be at least $11.75 million more than the initial purchase price. The debtor has scheduled an auction on May 22, 2024. At the auction, the subsequent bids would be in increments of $1 million. The stalking horse bidder would be entitled to a break-up fee of 3.5% of the purchase price and expense reimbursement of 1.5% of the purchase price in case of termination of the asset purchase agreement. The sale hearing is scheduled for May 24, 2024, in case no auction takes place and in case auction takes place will be scheduled for May 31, 2024.
공고 • Apr 03Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million on March 31, 2024. Baker & McKenzie LLP acted as a legal advisor to Acorda Therapeutics. Ernst & Young LLP, Investment Banking Arm acted as a financial advisor to Acorda Therapeutics. Freshfields Bruckhaus Deringer US LLP acted as a legal advisor to Merz Pharmaceuticals. Deloitte has acted as financial and tax advisors. Morgan Stanley acts as investment banker to Acorda Therapeutics. Perella Weinberg Partners acts as a investment banker to Merz Pharmaceuticals. Ducera Partners LLC acted as investment banker to Acorda Therapeutics. Leerink Partners LLC acted as a investment banker to Acorda Therapeutics.
공고 • Apr 02+ 1 more updateMotion for Joint Administration Filed by Acorda Therapeutics, Inc.Acorda Therapeutics, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on April 1, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Acorda Therapeutics Limited, Biotie Therapies AG, Biotie Therapies, LLC, Civitas Therapeutics, Inc. and Neuronex, Inc., with its own case for administrative and procedural purposes. Acorda Therapeutics, Inc. has been proposed as the lead debtor.
공고 • Mar 26Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024Acorda Therapeutics, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Apr 01, 2024
공고 • Nov 15Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. provides revenue guidance for the full year 2023. For the full year 2023, the Company reaffirms INBRIJA U.S. net revenue guidance to be $34-$38 million and AMPYRA net revenue guidance to be $65-$70 million.
공고 • Nov 07Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJAAcorda Therapeutics, Inc. announced the submission of new regulatory filings for the approval of INBRIJA® (levodopa inhalation powder) in six countries in Latin America by its partner Biopas Laboratories (Biopas). INBRIJA is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson's disease (PD) treated with carbidopa/levodopa. Biopas has submitted for marketing approval of INBRIJA in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings for approval of INBRIJA in Chile in late 2023 and in Mexico and Brazil in 2024.
공고 • Aug 11Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023Acorda Therapeutics, Inc. reaffirmed revenue guidance for the full year 2023. For the period, the company reaffirms net revenue to be $65 million to $70 million.
공고 • Jun 27Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5450(a)(1). Acorda is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq Global Select Market.
공고 • Jun 06Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select MarketAcorda Therapeutics, Inc. announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time June 5, 2023, and the Company's common stock will begin trading on a split-adjusted basis at the market open on June 5, 2023. The reverse stock split was effected to enable the Company to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. On November 11, 2022, the Company's stockholders authorized the board of directors to effect a reverse stock split by a ratio of any whole number in the range of 1-for-2 to 1-for-20 and a corresponding reduction in the number of authorized shares of common stock. The board of directors subsequently approved the reverse stock split and authorized the filing of the Company's amended and restated certificate of incorporation, as previously announced on May 31, 2023.
공고 • Jun 02Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued ListingAcorda Therapeutics, Inc. announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 4:01 p.m. Eastern Time, on June 2, 2023. The company’s common stock will begin trading on a post-split basis at the market open on June 5, 2023. The reverse stock split is being effected to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market. The reverse stock split will apply equally to all outstanding shares of the common stock, and each stockholder will hold the same percentage of common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares. The Company will not issue any fractional shares in connection with the reverse stock split, and the number of shares issued will be rounded up to the next whole share. The reverse stock split will not modify the rights or preferences of the common stock. As a result of the proportionate reduction in the number of authorized shares of common stock, the reverse stock split will result in the number of authorized shares of common stock being reduced from 61,666,666 to 3,083,333. As previously reported in the company’s Current Report on Form 8-K filed on November 14, 2022, on November 11, 2022, the company’s stockholders approved a proposal to authorize the company’s board of directors to approve an amendment and restatement of the company’s certificate of incorporation to effect a reverse stock split of the company’s common stock by a ratio of any whole number in the range of 1-for-2 to 1-for-20, and a corresponding reduction in the number of authorized shares of the company’s common stock, within one year following the conclusion of the Special Meeting of Stockholders on November 11, 2022.
Reported Earnings • May 15First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)First quarter 2023 results: US$0.69 loss per share (improved from US$1.85 loss in 1Q 2022). Revenue: US$22.3m (down 1.2% from 1Q 2022). Net loss: US$16.8m (loss narrowed 31% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
공고 • May 12Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023Acorda Therapeutics, Inc. reaffirmed earnings guidance for the year 2023. For the full year 2023, the company continues to target INBRIJA U.S. net revenue to be $38 million - $42 million and AMPYRA net revenue to be $65 million - $70 million.
Reported Earnings • Mar 11Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)Full year 2022 results: US$3.35 loss per share (improved from US$9.79 loss in FY 2021). Revenue: US$118.6m (down 8.1% from FY 2021). Net loss: US$65.9m (loss narrowed 37% from FY 2021). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
공고 • Feb 16Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price RequirementAcorda Therapeutics, Inc. announced that the Nasdaq Hearings Panel has granted the Company's extension request until June 20, 2023 to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. "We are pleased Nasdaq has granted us this extension," said Ron Cohen, M.D., Acorda's President and Chief Executive Officer. "We have announced a detailed business plan and long-term financial guidance to demonstrate what we believe is a path to growing shareholder value in Acorda. The key components of that plan are continued fiscal discipline, growing the Inbrija trajectory, and maintaining the Ampyra brand. We believe that it is in the best interests of our shareholders that we achieve compliance with the bid price rule organically by executing on that plan." If at any time before June 20, 2023 the bid price of Acorda's stock closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules. In the event that the Company cannot regain compliance organically during the extension period, the Company has committed to effecting a reverse stock split, which was authorized by shareholders in November 2022.
공고 • Dec 22Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A HearingAcorda Therapeutics, Inc. announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance with the minimum price of $1.00, the stock is subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to submit such request within the required seven calendar days, which will stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Hearings Panel following the hearing. The Hearings Panel has the discretion to grant the Company an extension through June 17, 2023. At the hearing, the Company intends to present a plan to achieve compliance with the Nasdaq listing requirements and to request additional time to regain such compliance. In the event that the Company receives an extension but cannot regain compliance within the extended time, the Company would effect a reverse stock split under authorization from stockholders received in November 2022. There can be no assurance that the Panel will grant the Company an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Global Select Market. “We believe it is in the best interests of shareholders to allow the stock price to grow organically rather than effecting a reverse stock split, and will discuss this and our long-term plan with the Hearings Panel,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer.
Reported Earnings • Nov 18Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 03Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)Third quarter 2022 results: US$0.57 loss per share (improved from US$2.43 loss in 3Q 2021). Revenue: US$33.5m (up 6.5% from 3Q 2021). Net loss: US$13.9m (loss narrowed 49% from 3Q 2021).
공고 • Oct 28Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027Acorda Therapeutics, Inc. Provided earnings guidance for the years of 2022, 2023, 2024, 2025, 2026 and 2027. For the year of 2022, the company expected net revenue to be USD 116.0 million to USD 119.7 million.For the year of 2023, the company expected net revenue to be USD 121.3 million to USD 134.3 million.For the year of 2024, the company expected net revenue to be USD 134.1 million to USD 148.1 million.For the year of 2025, the company expected net revenue to be USD 151.0 million to USD 166.8 million.For the year of 2026, the company expected net revenue to be USD 163.9 million to USD 181.2 million.For the year of 2027, the company expected net revenue to be USD 180.4 million to USD 199.3 million.
공고 • Oct 26Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022Acorda Therapeutics, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 01, 2022
공고 • Aug 20Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating OfficerAcorda Therapeutics, Inc. announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior Vice President, Operations & Strategic Planning and Susan Way, Senior Vice President, Drug Development and Regulatory Affairs.
Reported Earnings • Aug 06Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)Second quarter 2022 results: US$2.78 loss per share (down from US$2.29 loss in 2Q 2021). Revenue: US$31.1m (down 2.3% from 2Q 2021). Net loss: US$46.7m (loss widened 104% from 2Q 2021).
공고 • Aug 06Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022Acorda Therapeutics, Inc. provided revenue guidance for the full year 2022. For the full year 2022, Acorda continues to expect AMPYRA net revenue to be $68– $78 million.
공고 • Jun 25Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock MarketOn June 22, 2022, Acorda Therapeutics, Inc. (the Company") received a deficiency letter (the Notice") from the Listing Qualifications Department (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). The Notice has no immediate effect on the listing of the Company's common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during this 180-day period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The compliance period for the Company will expire on December 19, 2022.
공고 • May 17Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022For the full year 2022, Acorda Therapeutics, Inc. continues to expect AMPYRA net revenue to be $68 million– $78 million.
Reported Earnings • May 13First quarter 2022 earnings released: US$1.93 loss per share (vs US$3.53 loss in 1Q 2021)First quarter 2022 results: US$1.93 loss per share (up from US$3.53 loss in 1Q 2021). Revenue: US$22.5m (down 22% from 1Q 2021). Net loss: US$25.6m (loss narrowed 24% from 1Q 2021).
Board Change • May 03Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Mar 11Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: US$9.95 loss per share (up from US$12.32 loss in FY 2020). Revenue: US$129.1m (down 16% from FY 2020). Net loss: US$104.0m (loss widened 4.4% from FY 2020). Revenue exceeded analyst estimates by 2.9%.
공고 • Mar 07Acorda Therapeutics, Inc. Announces Board ChangesAcorda Therapeutics, Inc. announced on March 3, 2022, John Varian, one of the independent members of the company's Board of Directors, was appointed by the Board to serve on the Board's Audit Committee effective immediately. Mr. Varian was appointed to the Audit Committee to replace John Kelley, the Chair of the Board, who rotated off of the Committee upon Mr. Varian's appointment.
Board Change • Dec 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Independent Non-Executive Chairman John Kelley was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 11Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: US$31.5m (down 41% from 3Q 2020). Net loss: US$27.1m (down 468% from profit in 3Q 2020).
Executive Departure • Aug 26Independent Director Barry Greene has left the companyOn the 20th of August, Barry Greene's tenure as Independent Director ended after 14.6 years in the role. As of June 2021, Barry still personally held only 213.00 shares (€856 worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.
Executive Departure • Aug 26Independent Director Catherine D. Strader has left the companyOn the 22nd of August, Catherine D. Strader's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Catherine D.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 6.58 years.
Reported Earnings • Aug 09Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: US$31.8m (down 5.5% from 2Q 2020). Net loss: US$22.9m (loss widened 31% from 2Q 2020).
Reported Earnings • May 08First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$28.9m (up 2.7% from 1Q 2020). Net loss: US$33.5m (loss widened 417% from 1Q 2020).
공고 • May 07Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021Acorda Therapeutics, Inc. provided financial guidance for the full year of 2021. For the full-year 2021, the company continues to expect AMPYRA net revenue to be $75 million to $85 million.
Analyst Estimate Surprise Post Earnings • Mar 05Revenue beats expectationsRevenue exceeded analyst estimates by 2.8%. Over the next year, revenue is expected to shrink by 58% compared to a 62% growth forecast for the Biotechs industry in Germany.
Reported Earnings • Mar 05Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$153.0m (down 21% from FY 2019). Net loss: US$99.6m (loss narrowed 64% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 65% per year, which means it is significantly lagging earnings.
공고 • Feb 20Acorda Therapeutics Announces Executive ChangesAcorda Therapeutics, Inc. announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning from the Company effective mid-March, 2021. Mr. Lawrence will take a leadership position at an early-stage biotechnology company. Robert Morales, Acorda’s Vice President of Finance and Controller, will assume the roles of interim principal accounting officer and interim principal financial officer.
공고 • Feb 13Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million on January 12, 2021. The consideration is subject to certain adjustments and the assumption and is paid in cash. In connection with the transaction, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda. The Asset Purchase Agreement includes customary termination provisions in favor of the Acorda, on the one hand, and Catalent, on the other hand, including if the closing of the transaction has not occurred on or before May 12, 2021. As part of the transaction, Catalent will absorb all Acorda employees who work at the Chelsea facility and certain Acorda employees at the Waltham, Massachusetts facility. Completion of the transaction is subject to customary closing conditions, including, among others, the receipt of certain third party consents and approvals. The transaction is expected to close in the first quarter of 2021. The Acorda intends to use the net proceeds of $70 million received from the transaction for general corporate purposes, which may include funding capital expenditures and the repayment of indebtedness. MTS Health Partners, L.P. is serving as exclusive financial advisor to Acorda Therapeutics on the transaction. Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) on February 11, 2021.
공고 • Feb 12Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to CatalentAcorda Therapeutics, Inc. announced that it has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent. Under the terms of the agreement, Catalent has paid Acorda $80 million in cash, resulting in expected net proceeds to Acorda of approximately $74 million after transaction fees and expenses and settlement of customary post-closing adjustments. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda’s patients and continued adherence to best-in-class manufacturing quality and safety standards.
공고 • Jan 28Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic IndexAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index
공고 • Jan 14Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million.Catalent Pharma Solutions, Inc. entered into an asset purchase agreement to acquire INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR) for $80 million on January 12, 2021. The consideration is subject to certain adjustments and the assumption and is paid in cash. In connection with the transaction, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda. The Asset Purchase Agreement includes customary termination provisions in favor of the Acorda, on the one hand, and Catalent, on the other hand, including if the closing of the transaction has not occurred on or before May 12, 2021. As part of the transaction, Catalent will absorb all Acorda employees who work at the Chelsea facility and certain Acorda employees at the Waltham, Massachusetts facility. Completion of the transaction is subject to customary closing conditions, including, among others, the receipt of certain third party consents and approvals. The transaction is expected to close in the first quarter of 2021. The Acorda intends to use the net proceeds of $70 million received from the transaction for general corporate purposes, which may include funding capital expenditures and the repayment of indebtedness. MTS Health Partners, L.P. is serving as exclusive financial advisor to Acorda Therapeutics on the transaction.
Is New 90 Day High Low • Jan 14New 90-day high: €5.42The company is up 58% from its price of €3.42 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.
Reported Earnings • Nov 05Third quarter 2020 earnings released: EPS US$0.15The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$53.1m (up 11% from 3Q 2019). Net income: US$7.35m (up US$270.9m from 3Q 2019). Profit margin: 14% (up from net loss in 3Q 2019). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 67% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Nov 05Revenue beats expectationsRevenue exceeded analyst estimates by 79%. Over the next year, revenue is expected to shrink by 40% compared to a 305% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Nov 04New 90-day high: €0.89The company is up 55% from its price of €0.57 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
공고 • Oct 28Acorda Therapeutics, Inc. to Report Q3, 2020 Results on Nov 03, 2020Acorda Therapeutics, Inc. announced that they will report Q3, 2020 results at 4:30 PM, Eastern Standard Time on Nov 03, 2020
공고 • Oct 06Steven M. Rauscher to Resign as Member of Board of Directors of Acorda Therapeutics, IncOn September 30, 2020, Steven M. Rauscher notified Acorda Therapeutics, Inc. (the Company) of his decision to resign as a member of the Board of Directors of the Company, effective immediately. At the time of Mr. Rauscher's resignation, he was an independent director and member of the Audit Committee and Chair of the Compliance Committee. Mr. Rauscher indicated that his decision to resign was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
공고 • Sep 21Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI IndexAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from S&P Global BMI Index
공고 • Jul 02+ 3 more updatesAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value IndexAcorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Value Index
